medigraphic.com
Órgano Oficial del Instituto de Ciencias de la Salud, Hospital Escuela y Facultad de Medicina-Xalapa

2015, Number 1

<< Back Next >>

Rev Med UV 2015; 15 (1)

Mesenchymal stem cells: biology and use in hematopoietic stem cells trasnplantation

Castro MME, Montesinos MJJ

Language: Spanish
References: 35
Page: 38-44
PDF size: 554.41 Kb.


ABSTRACT

Mesenchymal stem cells are present in different tissues of an adult organism and also in neonatal sources and they can be considered as somatic stem cells. MSC were identified in bone marrow and have broad differentiation potential, capacity to support hematopoiesis and immunoregulatory properties. Because of these properties, there is a great expectation about their applications in cell therapy protocols for tissue regeneration. In particular, the application of MSC in clinical protocols to facilitate hematopoietic stem cells transplantation and to treat graft versus host disease is already a reality. However, although several studies have evidenced the beneficial effect of MSC in such clinical protocols, one of the main challenges is to increase knowledge in the biology of these cells. Therefore, further studies are necessary for optimal use of MSCs in cell therapy protocols. In this review we discuss the state of the art regarding biology of MSC and their use in hematopoietic cell transplantation.


REFERENCES

  1. Mayani H. Células troncales y medicina regenerativa: conceptos básicos, estado actual y perspectivas futuras. En: Células Troncales y Medicina Regenerativa. Pelayo R, Santana-Olalla J y Velasco I edt. Programa Universitario de Investigación en Salud (PUIS), México, 2011, 35-6.

  2. Montesinos JJ y Castro ME. Células Troncales Mesenquimales. En: Células Troncales y Medicina Regenerativa. Pelayo R, Santana-Olalla J y Velasco I edt. Programa Universitario de Investigación en Salud (PUIS), México, 2011, 119-38.

  3. Lemoli R, Bertolini F, Cancedda R, De Luca M, Del Santo A, Ferrari G, Ferrari S, Martino G, Mavilio F, Tura S. Stem cell plasticity: time for a reappraisal? Haematologica 2005; 90:360-81.

  4. Herzog E, Chai L, Krause DS. Plasticity of marrow-derived stem cells. Blood 2003; 15:3483-93.

  5. Watt F y Driskell R. The therapeutic potential of stem cells. Philos Trans R Soc Lond B BiolSci 2010; 12:155-63.

  6. Salem HK and Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010; 28:585-96.

  7. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luriá EA, Ruadkow IA. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974; 2:83-92.

  8. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-47.

  9. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-17.

  10. Montesinos JJ, Mora-García Mde L, Mayani H, Flores-Figueroa E, García-Rocha R, Fajardo-Orduña GR, Castro-Manrreza ME, Weiss- Steider B, Monroy-García A. In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity. Stem Cells and Development 2013; 22:2508-519.

  11. Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom M, MacArthur BD, Lira SA, Scadden DT, Ma’ayan A, Enikopolov GN and Frenette PS. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466:829-34.

  12. Zhang Y, Adachi Y, Suzuki Y, Minamino K, Iwasaki M, Hisha H, Song CY, Kusafuka K, Nakano K, Koike Y, Wang J, Koh E, Cui Y, Li C, Ikehara S. Simultaneos injección of bone marrow cells and stromal cells into bone marrow accelerates hematopoiesis in vivo. Stem Cells 2004; 22:1256-62.

  13. Anthony BA, Link DC. Regulation of hematopoietic stem cells by bone marrow stromal cells. Trends Immunol 2014; 35:32-7.

  14. Lai W, Li Y, Mak S, Ho F, Chow S, Chooi W, Chow Ch, Leung A, Chan B. Reconstitution of bone-like matrix in osteogenically differentiated mesenchymal stem cell-collagen constructs: A three-dimensional in vitro model to study hematopoietic stem cell niche. J Tissue Eng 2013; DOI: 10.1177/2041731413508668.

  15. Wagner W, Roderburg C, Wein F, Diehlmann A, Frankhauser M, Schubert R, Eckstein V, Ho AD. Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. Stem Cells 2007; 25:2638-647.

  16. Gottschling S, Saffrich R, Seckinger A, Krause U, Horsch K, Miesala K, Ho AD. Human mesenchymal stromal cells regulate initial selfrenewing divisions of hematopoietic progenitor cells by a beta1- integrin-dependent mechanism. Stem Cells 2007; 25:798-806.

  17. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 2:1550-561.

  18. Marta E. Castro Manrreza and Juan J. Montesinos. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. Journal of Immunology Research 2014. DOI: 10.1155/1607

  19. Chiesa S, Morbelli S, Morando S, Massollo M, Marini C, Bertoni A, Frassoni F, Bartolomé ST, Sambuceti G, Traggiai E, Uccelli A. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci USA 2011; 108:17384-389.

  20. Ghannam S, P`ene J, Torcy-Moquet G, Jorgensen C, and Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. Journal of Immunology 2010; 185:302–12.

  21. Castro-Manrreza ME, Mayani H, Monroy-García A, Flores-Figueroa E, Chávez-Rueda K, Legorreta-Haquet V, Santiago-Osorio E, Montesinos JJ. Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells. Stem Cells Dev 2014; 23:1217-32.

  22. Jitschin R, Mougiakakos D, Von Bahr L, Völkl S, Moll G, Ringden O, Kiessling R, Linder S, Le Blanc K. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. Stem Cells 2013; 31:1715-25.

  23. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killercell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111:1327-33.

  24. Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K. Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease. Transplantation 2006; 81:1390–97.

  25. Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, Longoni D, Pavan F, Masciocchi F, Algarotti A, Micò C, Grassi A, Deola S, Cavattoni I, Gaipa G, Belotti D, Perseghin P, Parma M, Pogliani E, Golay J, Pedrini O, Capelli C, Cortelazzo S, D’Amico G, Biondi A, Rambaldi A, Biagi E. Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: a Phase I Study on 40 Adult and Pediatric Patients. Biol Blood Marrow Transplant 2014; 20:375-81.

  26. Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, Mankuta D, Varda-Bloom N, Rheingold L, Yeshurun M, Bielorai B, Toren A, Zuckerman T, Nagler A, Or R. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res 2013; 19:225-38.

  27. Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, Taniguchi S, Imamura M, Ando K, Kato S, Mori T, Teshima T, Mori M, Ozawa K. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol 2013; 98:206-13.

  28. Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, Avanzini MA, Conforti A, Bertaina A, Giorgiani G, Jol-van der Zijde CM, Zecca M, Le Blanc K, Frassoni F, Egeler RM, Fibbe WE, Lankester AC, Locatelli F. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol 2013; 163:501-9.

  29. von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhäuser M. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009; 43:245-51.

  30. Müller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, Dominici M, Greil J, Handgretinger R. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008; 40:25-32.

  31. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, Yu Z, Li B, Xu C, Li Y, Wang J, Hu J, Lou X, Chen H. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008; 22:593-99.

  32. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ, Luo CW, Guo R, Ling W, Deng CX, Liao PJ, Xiang AP Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010; 45:1732-40.

  33. Peng Y, Chen X, Liu Q, Zhang X, Huang K, Liu L, Li H, Zhou M, Huang F, Fan Z, Sun J, Liu Q, Ke M, Li X, Zhang Q, Xiang AP. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia 2015; 29:636-46.

  34. Forslöw U, Blennow O, LeBlanc K, Ringdén O, Gustafsson B, Mattsson J, Remberger M. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2012; 89:220-27.

  35. Remberger M, Ringdén O. Treatment of severe acute graft-versushost disease with mesenchymal stromal cells: a comparison with non-MSC treated patients. Int J Hematol 2012; 96:822-24.




2020     |     www.medigraphic.com